1696 related articles for article (PubMed ID: 18816795)
1. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
3. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
6. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
7. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
8. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
10. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
Nosheny RL; Bachis A; Aden SA; De Bernardi MA; Mocchetti I
J Neurobiol; 2006 Oct; 66(12):1311-21. PubMed ID: 16967504
[TBL] [Abstract][Full Text] [Related]
11. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
12. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
13. Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat.
Mertens B; Massie A; Michotte Y; Sarre S
Neuroscience; 2009 Aug; 162(1):148-54. PubMed ID: 19383530
[TBL] [Abstract][Full Text] [Related]
14. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.
Bowenkamp KE; Hoffman AF; Gerhardt GA; Henry MA; Biddle PT; Hoffer BJ; Granholm AC
J Comp Neurol; 1995 May; 355(4):479-89. PubMed ID: 7636027
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
Natsume A; Mata M; Goss J; Huang S; Wolfe D; Oligino T; Glorioso J; Fink DJ
Exp Neurol; 2001 Jun; 169(2):231-8. PubMed ID: 11358438
[TBL] [Abstract][Full Text] [Related]
16. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
19. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.
Salvatore MF; Zhang JL; Large DM; Wilson PE; Gash CR; Thomas TC; Haycock JW; Bing G; Stanford JA; Gash DM; Gerhardt GA
J Neurochem; 2004 Jul; 90(1):245-54. PubMed ID: 15198683
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
